Lataa...
Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy
The US Food and Drug Administration approval of brentuximab vedotin (BV) in 2011 marked an important milestone in the management of classical Hodgkin lymphoma (HL). Although initially approved for use in the relapsed or refractory setting, its high efficacy and favorable toxicity profile led to nume...
Tallennettuna:
| Julkaisussa: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Päätekijä: | |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society of Hematology
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6246031/ https://ncbi.nlm.nih.gov/pubmed/30504312 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|